

Aviv Ladanie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7684008/publications.pdf>

Version: 2024-02-01

10
papers

223
citations

1163117

8
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

309
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Network Open, 2020, 3, e2024406.	5.9	53
2	Current use and costs of electronic health records for clinical trial research: a descriptive study. CMAJ Open, 2019, 7, E23-E32.	2.4	44
3	Interpretation of epidemiologic studies very often lacked adequate consideration of confounding. Journal of Clinical Epidemiology, 2018, 93, 94-102.	5.0	40
4	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. Journal of Clinical Epidemiology, 2019, 114, 49-59.	5.0	20
5	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Trials, 2018, 19, 505.	1.6	17
6	How to use FDA drug approval documents for evidence syntheses. BMJ: British Medical Journal, 2018, 362, k2815.	2.3	17
7	Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 118, 29-41.	5.0	13
8	Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. Journal of Clinical Epidemiology, 2018, 94, 35-45.	5.0	11
9	Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis. Journal of Clinical Epidemiology, 2019, 107, 12-26.	5.0	8
10	Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response. Journal of Clinical Epidemiology, 2018, 101, 127-128.	5.0	0